P3

EF-Tu-binding Re-complex antibiotics

Prof. Nils Metzler-Nolte, Ruhr-University of Bochum;  Prof. Julia Bandow, Ruhr-University of Bochum;  Sina Schäkermann, Ruhr-University of Bochum;  Daniel Siegmund, Ruhr-University of Bochum

PROvendis


Challenge

Infections with bacteria that are resistant to conventional antibiotics are increasing. Alternative antibiotics to overcome such resistances.


Technology

A series of novel Re(I)(CO)3–NHC complexes bearing unsubstituted benzimidazol-2-ylidene ligands as well as a variety of bisimine ligands has been prepared and comprehensively characterised. The complexes were found to exhibit potent antimicrobial activity on Gram-positive bacterial strains in the low micromolar concentration range, rendering these compounds interesting lead structures for the development of novel metal-based antibiotic agents.


Commercial Opportunity

The technology is offered for licensing and further therapeutic development.


Development Status

Compounds have been tested against Gram-positive bacteria.


Patent Situation

German priority application has been filed on July 7, 2017.


Further Reading

Siegmund, D, et al. (2017) Benzannulated Re(i)-NHC complexes: synthesis, photophysical properties and antimicrobial activity. Dalton Trans. 46: 15269-79.


 

EF-Tu-binding Re-complex antibiotics
EF-Tu-binding Re-complex antibiotics